Prerna K Chawla1, Shweta R Nanday2, Alpa J Dherai1,2, Rajeev Soman3, Rohan V Lokhande2, Prasad R Naik2, Tester F Ashavaid4,5. 1. Research Laboratories, P.D. Hinduja Hospital and Medical Research Centre, V.S. Marg, Mahim, Mumbai, 400016, India. 2. Department of Laboratory Medicine, P.D. Hinduja Hospital & Medical Research Centre, V.S. Marg, Mahim, Mumbai, 400016, India. 3. Department of Internal Medicine, P.D. Hinduja Hospital & Medical Research Centre, V.S. Marg, Mahim, Mumbai, 400016, India. 4. Research Laboratories, P.D. Hinduja Hospital and Medical Research Centre, V.S. Marg, Mahim, Mumbai, 400016, India. dr_tashavaid@hindujahospital.com. 5. Department of Laboratory Medicine, P.D. Hinduja Hospital & Medical Research Centre, V.S. Marg, Mahim, Mumbai, 400016, India. dr_tashavaid@hindujahospital.com.
Abstract
BACKGROUND: Voriconazole is an antifungal drug essentially metabolized by cytochrome P450 (CYP2C19) isozyme. Plasma voriconazole levels exhibit wide inter-individual variability due to several factors like age, weight, food or drug interactions or CYP2C19 polymorphisms. OBJECTIVE: In the present study, we assessed the correlation of voriconazole levels with CYP2C19 genotype in patients on voriconazole therapy. SETTING: Biochemistry Department of a 480 inpatient bed tertiary care hospital in India. METHODS: Plasma voriconazole estimation was done in seventy-two patients on standard weight based voriconazole therapy by High Performance Liquid Chromatography (HPLC) while genotype assessment for the CYP2C19*2 and *3 was done by PCR-RFLP and *17 by ARMS-PCR. Statistical analysis and genotype-phenotype correlation was done by comparing the drug levels with the CYP2C19 genotype. MAIN OUTCOME MEASURE: CYP2C19 polymorphisms influence voriconazole metabolism. RESULTS: A wide variability is seen in plasma levels with only 51% attaining therapeutic levels. The allele frequency of *2, *3 and *17 variant were found to be 33.3, 0.7 and 18% respectively. The drug levels in carriers of *2 allele (poor metabolizers) was twofold higher than that in extensive metabolizers. However, the influence of *2 allele was compromised in presence of *17 allele and patients had low voriconazole levels. In addition to the genotype, co-medication and clinical condition remarkably influenced voriconazole concentration. CONCLUSION: Plasma voriconazole levels are influenced by CYP2C19 variants, drug interactions and clinical condition of the patient. Genotype assessment at initiation of therapy followed by drug monitoring would help optimizing therapeutic efficacy and minimizing toxicity.
BACKGROUND:Voriconazole is an antifungal drug essentially metabolized by cytochrome P450 (CYP2C19) isozyme. Plasma voriconazole levels exhibit wide inter-individual variability due to several factors like age, weight, food or drug interactions or CYP2C19 polymorphisms. OBJECTIVE: In the present study, we assessed the correlation of voriconazole levels with CYP2C19 genotype in patients on voriconazole therapy. SETTING: Biochemistry Department of a 480 inpatient bed tertiary care hospital in India. METHODS: Plasma voriconazole estimation was done in seventy-two patients on standard weight based voriconazole therapy by High Performance Liquid Chromatography (HPLC) while genotype assessment for the CYP2C19*2 and *3 was done by PCR-RFLP and *17 by ARMS-PCR. Statistical analysis and genotype-phenotype correlation was done by comparing the drug levels with the CYP2C19 genotype. MAIN OUTCOME MEASURE: CYP2C19 polymorphisms influence voriconazole metabolism. RESULTS: A wide variability is seen in plasma levels with only 51% attaining therapeutic levels. The allele frequency of *2, *3 and *17 variant were found to be 33.3, 0.7 and 18% respectively. The drug levels in carriers of *2 allele (poor metabolizers) was twofold higher than that in extensive metabolizers. However, the influence of *2 allele was compromised in presence of *17 allele and patients had low voriconazole levels. In addition to the genotype, co-medication and clinical condition remarkably influenced voriconazole concentration. CONCLUSION: Plasma voriconazole levels are influenced by CYP2C19 variants, drug interactions and clinical condition of the patient. Genotype assessment at initiation of therapy followed by drug monitoring would help optimizing therapeutic efficacy and minimizing toxicity.
Entities:
Keywords:
CYP2C19; Genotype-phenotype correlation; India; Therapeutic drug monitoring; Voriconazole
Authors: Trana Hussaini; Maria J G T Rüping; Fedja Farowski; Janne J Vehreschild; Oliver A Cornely Journal: Pharmacotherapy Date: 2011-02 Impact factor: 4.705
Authors: Maud Berge; Romain Guillemain; David A Trégouet; Catherine Amrein; Veronique Boussaud; Patrick Chevalier; Agnes Lillo-Lelouet; Christine Le Beller; Pierre Laurent-Puig; Philippe H Beaune; Eliane M Billaud; Marie-Anne Loriot Journal: Eur J Clin Pharmacol Date: 2010-10-31 Impact factor: 2.953
Authors: Steve Trifilio; Gennethel Pennick; Judy Pi; Jennifer Zook; Mary Golf; Kimberley Kaniecki; Seema Singhal; Stephanie Williams; Jane Winter; Martin Tallman; Leo Gordon; Olga Frankfurt; Andrew Evens; Jayesh Mehta Journal: Cancer Date: 2007-04-15 Impact factor: 6.860
Authors: S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2013-05-22 Impact factor: 6.875
Authors: Issam S Hamadeh; Kenneth P Klinker; Samuel J Borgert; Ashley I Richards; Wenhui Li; Naveen Mangal; John W Hiemenz; Stephan Schmidt; Taimour Y Langaee; Charles A Peloquin; Julie A Johnson; Larisa H Cavallari Journal: Pharmacogenet Genomics Date: 2017-05 Impact factor: 2.089